J07BN02 · Anti-infectives for systemic use
Jcovden (previously COVID-19 Vaccine Janssen)
Indications
Jcovden is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Composition
- Active substance
- adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)
- International name (INN)
- COVID-19 vaccine (Ad26.COV2-S [recombinant])
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jcovden (previously COVID-19 Vaccine Janssen)
- Active substance
- adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)
- ATC code
- J07BN02